Sorafenib

製品コードS7397 別名:BAY 43-9006

Sorafenib化学構造

分子量(MW):464.82

Sorafenibは一種のRaf-1、 B-RafとVEGFR-2の多種キナーゼ阻害剤で,無細胞試験でIC50値が6 nM、22 nMと90 nMにそれぞれ分かれることです。

サイズ 価格(税別)  
JPY 24402.00
JPY 44820.00
JPY 111220.00

文献中の使用例(62)

カスタマーフィードバック(9)

  • Inhibition of the MAPK signaling pathway results in downregulation of Plk-1 protein expression. (a) WB analysis for Plk-1 protein after treatment of human melanoma cell lines M14 and WM-115 with MEK 1/2 inhibitor PD98059 (10 μM), JNK inhibitor (16 μM), p38 inhibitor SB203580 (20 μM), and multikinase inhibitor sorafenib (10 μM) for 48 h showing significant reduction in the expression of Plk-1 protein after 48 hours. (b) Annexin V/PI staining of cells treated with MAPK inhibitors and induction of apoptosis. JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase kinase 1/2; Plk-1, polo-like kinase 1; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. Sorafenib purchased from Selleck.

    (A) were exposed to 200 uM gentamicin for various time periods. Immunoreactivity for phosphorylated JNK (green) and c-Jun (blue) in hair cells increased in a time-dependent manner. B. Hair cells from explants pre-treated with 500 nM sorafenib displayed a near complete inhibition of JNK activation at all time points analyzed.

    J Neurosci 2013 33(7), 3079-93. Sorafenib purchased from Selleck.

  • Sorafenib in combination with metformin or the AMPK activator salicylate enhances AMPK activation. a, b, AMPK activation with the combination of sorafenib and metformin in LKB1 mutant KRAS mutant (A549 and H460) NSCLC cells (a), LKB1 wild-type KRAS mutant (H358) (b, left panel) or LKB1 mutant KRAS wild-type (H838) NSCLC cells (b, right panel). Cells were treated for 48 hr with sorafenib (1-3 uM), metformin (1–1.5 mM) or the combination of sorafenib and metformin with the same concentrations as were used for the individual treatments. c, AMPK activation with the combination of sorafenib and salicylate in LKB1 mutant KRAS mutant (A549 and H460) or LKB1 mutant KRAS wild-type (H838) NSCLC cells. Cells were treated for 48 hr with sorafenib (1–3 uM), salicylate (1–1.5 mM) or the combination of sorafenib and salicylate with the same concentrations as were used for the individual treatments. Cell lysates were harvested for western blot analysis and probed with the indicated antibodies.

    Int J Cancer 2012 10.1002/ijc.29113.. Sorafenib purchased from Selleck.

    Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.

    Mol Cancer Res 2014 12(10), 1377-87. Sorafenib purchased from Selleck.

  • HCC cell-derived exosomes reverse sorafenib-induced apoptosis in hepatoma carcinoma cells in vivo. a Tumors from mice treated with PBS (Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib + MHCC-97H-exosomes (Sora + 97H exo) were paraffin-embedded and sectioned, followed by staining of apoptotic cell by using TUNEL assays.

    J Exp Clin Cancer Res, 2016, 35(1):159. Sorafenib purchased from Selleck.

    Sorafenib and PX-866 interact to suppress tumor growth in vivo. Mice were PO administered vehicle diluent, sorafenib (25 mg/kg), PX-866 (2 mg/kg), or the drug combination QD for 3 days. Animals were monitored daily and tumor volume determined every fifth day. Tumors from animals were isolated at day 15 and fixed, sectioned (10-um), and stained against proliferation (Ki67 staining), phospho-ERK1/2 and phospho-AKT staining, the levels of tumor cell apoptosis/cleaved caspase 3, as well as with H&E and 4′,6-diamidino-2-phenylindole (DAPI).

    Mol Pharmacol 2013 84(4), 562-71. Sorafenib purchased from Selleck.

  • Effects of sorafenib or sunitinib on LicA-induced cell death, ER stress responses, PLCc1, Ca2+, and ROS in HepG2 cells. HepG2 cells were pretreated with sorafenib or sunitinib for 1 h, then treated with LicA or TG for 1 h (for P-eIF2a and P-PLCc1) or 24 h (for CHOP, ATF6a(p90), and caspase-4). The cell lysates were subjected to Western blot analyses using antibodies against CHOP, ATF6a(p90), caspase-4(C), P-eIF2a, and b-actin.

    Apoptosis 2014 19(4), 682-97. Sorafenib purchased from Selleck.

    PLoS One 2013 8(1), e54595. Sorafenib purchased from Selleck.

  • (C) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in HUH-7 and R-HUH-7 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (D) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in SK-HEP-1 and R-SK-HEP-1 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (E) HUH-7 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. (F) SK-HEP-1 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. Data were expressed as mean ± standard deviation of each experiment in triplicate. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. Sorafenib purchased from Selleck.

製品安全説明書

Raf阻害剤の選択性比較

生物活性

製品説明 Sorafenibは一種のRaf-1、 B-RafとVEGFR-2の多種キナーゼ阻害剤で,無細胞試験でIC50値が6 nM、22 nMと90 nMにそれぞれ分かれることです。
ターゲット
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
体外試験

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NX7XRWVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMECwNFA{ODNizszN MlPCV2FPT0WU
MONO-MAC-6 MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DL[WlEPTB;MD6wNFQyQCEQvF2= NFjKcmNUSU6JRWK=
ALL-PO M4P4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zRfGlEPTB;MD6wN|E5PCEQvF2= NWKw[mxGW0GQR1XS
NKM-1 NGPhcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMEe0NVYh|ryP Ml3kV2FPT0WU
CGTH-W-1 M{nSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;0TWM2OD1yLkK1NFIzKM7:TR?= M4nweXNCVkeHUh?=
BB65-RCC Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL4TWM2OD1yLkS3NFc{KM7:TR?= MW\TRW5ITVJ?
NOS-1 M1vESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwNU[zOkDPxE1? NFqzOpBUSU6JRWK=
SH-4 M2n3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvrW5JKSzVyPUCuOlU3OTNizszN M2TS[XNCVkeHUh?=
HOP-62 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmf5TWM2OD1yLki1NFg5KM7:TR?= NXTmR3dRW0GQR1XS
HCC2998 MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[5TWM2OD1yLki4PFE5KM7:TR?= NI\1V4tUSU6JRWK=
GDM-1 Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe0elFKSzVyPUCuPVA3QThizszN MXTTRW5ITVJ?
KM12 NH[4OmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL3Z2ZGUUN3ME2xMlAzODl6IN88US=> MoHvV2FPT0WU
LB2518-MEL NWTic5J4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDkOW14UUN3ME2xMlIxQDB7IN88US=> NXTSOlhrW0GQR1XS
NCI-H1436 NUTsUFRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwMkG2O|gh|ryP NGfJcWhUSU6JRWK=
EM-2 Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rsdWlEPTB;MT6zOVU4QCEQvF2= M3PZUHNCVkeHUh?=
LAMA-84 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LXWGlEPTB;MT6zO|Y1QCEQvF2= MVzTRW5ITVJ?
KG-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrRNZNKSzVyPUGuOFc6OzVizszN NXrpc4lVW0GQR1XS
A388 NHX4eJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFwNUmxOlUh|ryP NFfsbVZUSU6JRWK=
no-10 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL6S3V3UUN3ME2xMlYyPzJ4IN88US=> MVXTRW5ITVJ?
SF126 NYDabohzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\qPWZKSzVyPUGuOlM5OTJizszN M1rpfnNCVkeHUh?=
MEG-01 NYW0fGhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\wVphKSzVyPUGuPFA6QCEQvF2= NV7oVmlrW0GQR1XS
A3-KAW MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFwOEi0NkDPxE1? NFPQWVRUSU6JRWK=
D-247MG NFTyd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nLd2lEPTB;Mj6xOFQ5KM7:TR?= M2m2e3NCVkeHUh?=
OVCAR-4 NV3WWGt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[2WmlEPTB;Mj6yNVM6OyEQvF2= MmnHV2FPT0WU
NCI-SNU-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLlTWM2OD1{LkOxOlIh|ryP MUDTRW5ITVJ?
NCI-H2171 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3FTWM2OD1{LkO5O|Y1KM7:TR?= NUXnO|M{W0GQR1XS
SIG-M5 NHe5WHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X4V2lEPTB;Mj60NlI1OiEQvF2= MWPTRW5ITVJ?
BE-13 M3robGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jyXGlEPTB;Mj62PVYxQSEQvF2= MX\TRW5ITVJ?
K052 MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\iUJBKSzVyPUKuO|Q3OTZizszN M{i2OXNCVkeHUh?=
L-540 M1;Ec2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;CUmtkUUN3ME2yMlc2Pzh7IN88US=> MkXWV2FPT0WU
KMOE-2 NYTDXXp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PVVGlEPTB;Mj64NVM2KM7:TR?= NVHO[JhvW0GQR1XS
MFH-ino MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rYWGlEPTB;Mj65NlE5PSEQvF2= NXfhU292W0GQR1XS
HL-60 NFvEe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvlTWM2OD1|LkC2Nlk6KM7:TR?= MV\TRW5ITVJ?
HCC2218 NYL5d3lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TWS2lEPTB;Mz6xNlAxOyEQvF2= NIPaPYtUSU6JRWK=
TE-5 MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq0TWM2OD1|LkGzNVYzKM7:TR?= M2r4[XNCVkeHUh?=
MZ1-PC MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M32zTmlEPTB;Mz60O|UxQSEQvF2= M2Lkd3NCVkeHUh?=
MRK-nu-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjvXpZ1UUN3ME2zMlYyPDZ6IN88US=> NGCzXJBUSU6JRWK=
MZ7-mel M3jQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO0TWM2OD1|Lk[2NFk6KM7:TR?= MYnTRW5ITVJ?
BC-1 M2e3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTNwN{SwNkDPxE1? Mn\oV2FPT0WU
ST486 NGXHV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ntZWlEPTB;Mz64N|Y4OyEQvF2= MXjTRW5ITVJ?
KS-1 MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DGcGlEPTB;Mz64PFE6QCEQvF2= MnH1V2FPT0WU
SK-NEP-1 M2fnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS0NGNKSzVyPUSuNVY5OTVizszN NHnvU2VUSU6JRWK=
BC-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[yU45yUUN3ME20MlI{OzlzIN88US=> NWHscWVkW0GQR1XS
NCI-H1581 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPFTWM2OD12LkK4O|k5KM7:TR?= Mm\CV2FPT0WU
MHH-PREB-1 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnnTWM2OD12LkSwOFg1KM7:TR?= NYfkR|Q{W0GQR1XS
NOMO-1 Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\4VWlEPTB;ND60PFkxPSEQvF2= M1TMZXNCVkeHUh?=
QIMR-WIL MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fk[2lEPTB;NT6wO|I6PCEQvF2= NWPXZZJPW0GQR1XS
SF539 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLTW5FSUUN3ME21MlE{OjJ5IN88US=> NGHHRWFUSU6JRWK=
TE-12 M4XleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIOzdJFKSzVyPUWuNlQ6OjlizszN Mk\jV2FPT0WU
NCI-H510A MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX6TWM2OD13LkSxOlg2KM7:TR?= NWfOd28{W0GQR1XS
JAR M1P0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrEUIc4UUN3ME21MlUxQDJ2IN88US=> MYnTRW5ITVJ?
no-11 M{\ySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPJc5RKSzVyPUWuO|M2PjhizszN MXjTRW5ITVJ?
BV-173 M4HF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTVwOUW2PFIh|ryP NEexNZpUSU6JRWK=
SR NHP2eG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrONlBKSzVyPU[uNFA3PzhizszN NUjTWIw4W0GQR1XS
MOLT-16 MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1flc2lEPTB;Nj6yOVI3PiEQvF2= NHe2OWlUSU6JRWK=
MZ2-MEL NW\LO2FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDHTWM2OD14LkOxPFM6KM7:TR?= NVT3W4lTW0GQR1XS
SW954 NVLBTW9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELJbIJKSzVyPU[uOFU5PjZizszN M4fxdXNCVkeHUh?=
ML-2 NYPMepJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLIPJpKSzVyPU[uOVI5PDlizszN NGmxdZJUSU6JRWK=
OCI-AML2 MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{H4ZmlEPTB;Nj62NVA3OiEQvF2= NGCzdZRUSU6JRWK=
SIMA MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnS5TWM2OD15LkCwNVAyKM7:TR?= NEXvXplUSU6JRWK=
DOHH-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojFTWM2OD15LkC1Olc3KM7:TR?= Mnf6V2FPT0WU
697 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS0dVVKSzVyPUeuNFU6QDlizszN MlXlV2FPT0WU
NB1 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkj2TWM2OD15LkSwOFA4KM7:TR?= MX\TRW5ITVJ?
D-392MG MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\ETWM2OD15Lk[yOlY{KM7:TR?= MYXTRW5ITVJ?
ES8 NWf0e3NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NICx[HdKSzVyPUeuO|Y2ODNizszN NFfSc5RUSU6JRWK=
RPMI-8226 NILheWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7QS5lKSzVyPUeuPFQ2OTFizszN MWTTRW5ITVJ?
IST-MEL1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRThwNECwNFIh|ryP M2TvXXNCVkeHUh?=
NB14 NGm4eGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH2TWM2OD16Lk[zNVM{KM7:TR?= M2H4O3NCVkeHUh?=
HD-MY-Z NYfqPHZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRThwNkO3OFYh|ryP M1nXTXNCVkeHUh?=
TE-10 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4iwdmlEPTB;OD63OlM2OyEQvF2= MUDTRW5ITVJ?
LC-1F MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTlwMUC4N|Qh|ryP Mn7vV2FPT0WU
OS-RC-2 NV[4U21CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M173dWlEPTB;OT6xNVI1OyEQvF2= NFrDSm5USU6JRWK=
NCI-SNU-16 NEjEUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorDTWM2OD17LkKxNFI3KM7:TR?= M4rIZXNCVkeHUh?=
SHP-77 M1f1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTKUWhQUUN3ME25MlcyPjZ{IN88US=> MYnTRW5ITVJ?
A4-Fuk NIeydG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPhTWM2OD17Lke1OlEh|ryP M{DxVXNCVkeHUh?=
NB6 NUTGU|J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrySnZCUUN3ME25Mlc3ODJ7IN88US=> NYm0O3piW0GQR1XS
JiyoyeP-2003 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXhU29KSzVyPUGwMlQ4PDVizszN M3e0Z3NCVkeHUh?=
DMS-114 NVK4U2tOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\QPFhKSzVyPUGwMlU1PDFizszN MVjTRW5ITVJ?
NB7 NHzhPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXCTWM2OD1zMD63OVI3KM7:TR?= NUjvSpBHW0GQR1XS
NCI-H747 NX\sUWZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvYTWM2OD1zMT6xNlE3KM7:TR?= NIX3XVdUSU6JRWK=
HH NFnjW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn4Wo9EUUN3ME2xNU4{QDd4IN88US=> NGTmN4lUSU6JRWK=
EW-18 M4\qV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT5eo9KSzVyPUGxMlkxPDRizszN MXnTRW5ITVJ?
CHP-126 NGHBZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13yfGlEPTB;MUGuPVc{QCEQvF2= MnnUV2FPT0WU
NTERA-S-cl-D1 NEC3fJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fGSWlEPTB;MUKuNFI4QCEQvF2= NYTjOph2W0GQR1XS
DEL M4TsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7iTWM2OD1zMj6wPVg2KM7:TR?= MYPTRW5ITVJ?
LU-139 MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF{LkW0NVMh|ryP NWXkNZFZW0GQR1XS
P30-OHK M2DMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3L6OWlEPTB;MUKuOVQ4QSEQvF2= MXvTRW5ITVJ?
NCI-H1522 MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrhZ2pUUUN3ME2xNk44PDZizszN NGW0SVRUSU6JRWK=
NCI-H1299 NEX2[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:5bpJGUUN3ME2xN{4zQTFzIN88US=> NIjtcGRUSU6JRWK=
UACC-257 NETTWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\xU2lEPTB;MUOuOVEzPiEQvF2= NYDTR45sW0GQR1XS
Calu-6 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVf0R4VIUUN3ME2xN{43ODR4IN88US=> MVHTRW5ITVJ?
NCI-H1882 NY\5RWE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPybG1KSzVyPUGzMlg2PTVizszN MVrTRW5ITVJ?
BB30-HNC M{H3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3WTWM2OD1zND6wOlA6KM7:TR?= MkD2V2FPT0WU
ES1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLYNpFKSzVyPUG0MlE2PTFizszN Mn22V2FPT0WU
NCI-H1694 MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1O1RmlEPTB;MUSuOFgyOSEQvF2= M3H3XXNCVkeHUh?=
IST-SL1 NFPVcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn6XW5KSzVyPUG0Mlk3OTZizszN MnrNV2FPT0WU
ECC4 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF3LkC1OVgh|ryP NVnYUZkzW0GQR1XS
MDA-MB-134-VI NYDDboh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF3LkSxN|Eh|ryP M1j3bXNCVkeHUh?=
SCH MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fCTWlEPTB;MUWuOFczQCEQvF2= NHzFSIlUSU6JRWK=
SK-N-FI M1;LVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzkTWM2OD1zNT62OVM1KM7:TR?= NELSZY5USU6JRWK=
HDLM-2 NXe5NmZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF4LkC3NVQh|ryP NI[2UmhUSU6JRWK=
Ramos-2G6-4C10 NXzGdGlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF4LkGyPVch|ryP NGTzToVUSU6JRWK=
EW-24 NH\PWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF4LkG2OlEh|ryP Ml3iV2FPT0WU
NCI-H2141 M1\EPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXjVoJEUUN3ME2xOk4yQDlizszN Mki3V2FPT0WU
LC4-1 M2XVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF4Lk[xNVkh|ryP NIfB[2dUSU6JRWK=
HT-144 M1f3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzOTWM2OD1zNz6wNFYh|ryP NH3sXGFUSU6JRWK=
SK-MEL-1 NETjSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF5LkCwO|Ih|ryP Ml\zV2FPT0WU
SCC-15 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[2UmlEPTB;MUeuNVY{QCEQvF2= M1Th[nNCVkeHUh?=
C8166 NFi4So1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlewTWM2OD1zNz62PFM{KM7:TR?= MYXTRW5ITVJ?
GOTO NUPCO2VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLPTWM2OD1zNz64N|Q1KM7:TR?= NFLaXIxUSU6JRWK=
COR-L279 M172emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\PTWM2OD1zOD6xN|YzKM7:TR?= M4PrUnNCVkeHUh?=
K-562 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rRXWlEPTB;MUiuO|E1OyEQvF2= NIPldFNUSU6JRWK=
ES3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWCx[41KUUN3ME2xPE45ODRzIN88US=> NYj0TFVEW0GQR1XS
LU-165 MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW5TWM2OD1zOT63NFA5KM7:TR?= NELsbJBUSU6JRWK=
KM-H2 NV35eXhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LnbmlEPTB;MkCuN|E5PCEQvF2= NY\TXW5OW0GQR1XS
RL MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJyLkm2PVIh|ryP MYPTRW5ITVJ?
EW-3 NEjZSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PMTWlEPTB;MkGuNVg5QSEQvF2= M2mwNnNCVkeHUh?=
A101D MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJzLkO3OVIh|ryP NE\PO4NUSU6JRWK=
HUTU-80 NHv2d5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPWbmJKSzVyPUKxMlM6PDZizszN NHzaeI9USU6JRWK=
NCI-H23 M1jWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPPd3o5UUN3ME2yNU4{QTl{IN88US=> NXnqb5JmW0GQR1XS
PF-382 NGHzTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEiyOnlKSzVyPUKxMlQ1ODNizszN MVPTRW5ITVJ?
LB373-MEL-D MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHRTWM2OD1{MT61OlE2KM7:TR?= MljKV2FPT0WU
TE-8 M{T2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJzLk[zPVQh|ryP MWfTRW5ITVJ?
TE-9 NHXKRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO2TWM2OD1{MT64OVE{KM7:TR?= NGrlbmZUSU6JRWK=
Daudi NH;MVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTsTnlKSzVyPUKxMlk{ODRizszN M3uycnNCVkeHUh?=
D-542MG M3TaWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUiybWRVUUN3ME2yNk4xOjV4IN88US=> MUnTRW5ITVJ?
U-698-M NH7hVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3Ec3V4UUN3ME2yNk41PjB|IN88US=> NUfBTXZFW0GQR1XS
ES6 NEXxVnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJ{LkezOlYh|ryP NH7GOnRUSU6JRWK=
DU-4475 M4SwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zkZmlEPTB;MkOuPFg6PyEQvF2= NX3xNnF2W0GQR1XS
ECC12 NETqXo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX4TWM2OD1{ND6yPFA{KM7:TR?= NXnMZlRUW0GQR1XS
C2BBe1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjtRmtKSzVyPUK0MlMzOzlizszN NUPMR3FHW0GQR1XS
IST-SL2 MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojFTWM2OD1{ND60N|YzKM7:TR?= MmSzV2FPT0WU
DJM-1 MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTJ2LkWyNlEh|ryP NXTP[HBoW0GQR1XS
DMS-153 MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJ2Lki2NVQh|ryP MY\TRW5ITVJ?
NB13 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPsO2tuUUN3ME2yOU4xOjZ3IN88US=> MX3TRW5ITVJ?
SK-N-DZ M{HhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPnTWM2OD1{Nj6zOFE1KM7:TR?= MYLTRW5ITVJ?
COR-L88 MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPvdZJsUUN3ME2yOk42Pzl4IN88US=> MnHMV2FPT0WU
LU-65 M1XiSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W0fWlEPTB;Mk[uPFU{PSEQvF2= NE\IZoRUSU6JRWK=
TGBC1TKB NYHVdpd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvoTWM2OD1{Nj65PFI5KM7:TR?= Ml\pV2FPT0WU
THP-1 NV\TeFJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17WPWlEPTB;MkeuNlE1OSEQvF2= NHnUWJZUSU6JRWK=
ONS-76 NXjS[W1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j0cGlEPTB;MkeuN|MzKM7:TR?= M1PFe3NCVkeHUh?=
LC-2-ad NEnDTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrvTWM2OD1{Nz62NlMyKM7:TR?= MWjTRW5ITVJ?
EW-13 MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDSW4RKSzVyPUK5MlE4PDZizszN NH\KT3FUSU6JRWK=
MS-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGP4[|VKSzVyPUOwMlczPzhizszN MkLTV2FPT0WU
NCI-H2227 NWLLVHFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTNyLkm4NFYh|ryP NIK5NZJUSU6JRWK=
LXF-289 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELDRmxKSzVyPUOxMlQ1QTJizszN M4HqVHNCVkeHUh?=
MC116 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zKc2lEPTB;M{KuNFgzPiEQvF2= M3W4V3NCVkeHUh?=
EVSA-T MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3DOZhKSzVyPUOyMlI2QDVizszN M3\QNXNCVkeHUh?=
CTB-1 Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnicHRTUUN3ME2zN{4yOTBzIN88US=> MVLTRW5ITVJ?
COLO-320-HSR MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\BTWM2OD1|Mz6xOlA{KM7:TR?= M3G5fXNCVkeHUh?=
NCI-H2196 M4HBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUe4NXc2UUN3ME2zN{4zPTV5IN88US=> NHnOU5RUSU6JRWK=
LB2241-RCC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL3WFNKSzVyPUOzMlMyOzVizszN NX7FVJRLW0GQR1XS
LS-513 NHzNTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr6SpVKSzVyPUOzMlg3OzhizszN M4rpSXNCVkeHUh?=
LP-1 MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnZbW1KSzVyPUOzMlk6PTZizszN NHTBXmdUSU6JRWK=
A253 NIfTeZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoO4TWM2OD1|ND6yNlk3KM7:TR?= NUDjUWFyW0GQR1XS
SK-MM-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi3b5dbUUN3ME2zOE46PDVzIN88US=> M2PCdnNCVkeHUh?=
NCI-H1963 MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzmN4tCUUN3ME2zOU4{ODd{IN88US=> NXHXblhtW0GQR1XS
MMAC-SF MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj5TWM2OD1|NT64O|g2KM7:TR?= MUHTRW5ITVJ?
LB831-BLC NIDtUGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTN4LkC2OVQh|ryP NHnMUXRUSU6JRWK=
WSU-NHL NH64fZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm1TWM2OD1|Nj6xOlQh|ryP MWfTRW5ITVJ?
CESS NIj6boJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PzUGlEPTB;M{[uNlg1QCEQvF2= NEPoVlJUSU6JRWK=
NEC8 NV3WUHJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHGTWM2OD1|Nj61PFM2KM7:TR?= NE\EWlJUSU6JRWK=
KNS-42 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK5bWNKSzVyPUO3MlEzOzdizszN M2LOVnNCVkeHUh?=
MHH-CALL-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW1TWM2OD1|Nz6xPFIyKM7:TR?= M1rBWnNCVkeHUh?=
K5 NVTCb|A5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfHTWM2OD1|OD60N{DPxE1? MXnTRW5ITVJ?
CP66-MEL NYn4TWhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\DU2lEPTB;M{muNFc{OyEQvF2= NGrIUmlUSU6JRWK=
OPM-2 Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTN7Lki0N|Ih|ryP M4\zVnNCVkeHUh?=
IST-MES1 NFHo[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV6zeWpCUUN3ME20NE4{ODl4IN88US=> Mni4V2FPT0WU
EC-GI-10 M2D3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[4bYR3UUN3ME20NU42QDB3IN88US=> M1LBZnNCVkeHUh?=
CTV-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLjTWM2OD12Mj64OFA3KM7:TR?= NWTzRnRGW0GQR1XS
DG-75 Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIruR5JKSzVyPUSzMlc2QTVizszN MXLTRW5ITVJ?
KNS-81-FD M3Hzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnQS4RVUUN3ME20OU41ODV6IN88US=> NU\aUJlDW0GQR1XS
NCI-H82 MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLjTWM2OD12NT61O|U5KM7:TR?= NEXJcHBUSU6JRWK=
RPMI-8866 M1TYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2i5e2lEPTB;NE[uNVg4OyEQvF2= MXfTRW5ITVJ?
ACN NFzleXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjwRoZKSzVyPUS2MlQ{PCEQvF2= M4fxXXNCVkeHUh?=
NCI-H1395 MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTpTWM2OD12Nj60O|U3KM7:TR?= M3LBcXNCVkeHUh?=
NCI-H209 NVzocYdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULZTJk5UUN3ME20O{4yPDB3IN88US=> NFPMVoVUSU6JRWK=
TGW M1q2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT3WXc1UUN3ME20PU4xPzlzIN88US=> NXf4[3NZW0GQR1XS
NCI-H748 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DyNmlEPTB;NEmuOFc2OyEQvF2= M{Tl[HNCVkeHUh?=
EKVX Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTE[5V1UUN3ME20PU43PjJ6IN88US=> NIDVV25USU6JRWK=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
細胞試験:

[1]

+ 展開
  • 細胞株: MDA-MB-231, and HAoSMC
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • 製剤: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • 投薬量: ~60 mg/kg
  • 投与方法: Orally once daily
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 63 mg/mL (135.53 mM) warming
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
5% DMSO+45% PEG 400+ddH2O
3mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 464.82
化学式

C21H16ClF3N4O3

CAS No. 284461-73-0
保管
別名 BAY 43-9006

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00727233 Completed Neurofibromatosis Type I|Plexiform Neurofibroma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 8, 2008 Phase 1
NCT02989870 Not yet recruiting HepatoCellular Carcinoma|Unresectable HepatoCellular Carcinoma|Liver Cancer H. Lee Moffitt Cancer Center and Research Institute|National Comprehensive Cancer Network April 30, 2017 Phase 1
NCT01445080 Completed Leukemia|With AML and FLT3-ITD Mutations National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 23, 2006 Phase 1
NCT01434602 Recruiting Brain Tumor|Glioblastoma|Anaplastic Glioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 21, 2015 Phase 1|Phase 2
NCT02988440 Not yet recruiting Hepatocellular Carcinoma Novartis Pharmaceuticals|Novartis May 2017 Phase 1
NCT03037437 Not yet recruiting Hepatocellular Cancer The University of Texas Health Science Center at San Antonio January 2017 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Related Antibodies

Raf信号経路図

相関Raf製品

Tags: Sorafenibを買う | Sorafenib ic50 | Sorafenib供給者 | Sorafenibを購入する | Sorafenib費用 | Sorafenib生産者 | オーダーSorafenib | Sorafenib化学構造 | Sorafenib分子量 | Sorafenib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID